A set of optimised protocols and MRI methods to measure CBF that will have been cross-validated and tested on all major MRI scanner platforms present in Europe.
Clear directives established in coordination with the major European bodies on the use of these new tools and their limitations.
Published paper: Alsop DC, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2015;73(1):102-106
An increased capacity building of researchers in this particular field.
Two Schools were run in the 3rd year of the Action, both full with 50 students each, directly contributing to the number of new people working in the field. The Action grew to more than 200 people by the 4th year, a demonstration of its positive effect on the field.
Improved collaborations with the major pharmaceutical industries developing new therapies for AD and other dementia.
Mediri GmbH, a company led by the Vice Chair of the Action, has started several clinical trials in which ASL is a key component. Other clinicians around the Action also took part is such clinical trials. Finally, several members from the Action were involved in the setup of ASL as part of the EU IMI Pharmacog study (http://www.alzheimer-europe.org/Research/PharmaCog)